COVID-19 Monoclonal Antibody Treatment
If you have a positive COVID-19 test and are experiencing mild to moderate symptoms, you might be eligible for monoclonal antibody therapy. Spectrum Health West Michigan operates an infusion clinic at Spectrum Health Blodgett Hospital that uses monoclonal antibodies for the treatment of COVID-19 under a U.S. Food and Drug Administration Emergency Use Authorization.
To be considered for this treatment option, patients must be 12 years of age or older and meet the following initial criteria:
- Positive COVID-19 test
- COVID-19 related symptoms have been present for less than 10 days
- Patient is not hospitalized
- You have one or more risk factors for disease progression. These risk factors are determined by your a COVID-19 infusion clinic provider over the phone.
To schedule an appointment, please contact us at 616.391.0351. Patients at Spectrum Health Lakeland should talk with their primary care provider or click here to learn more. Click here for fact sheets as well as an FAQ from the U.S. Food and Drug Administration.*
*Statements required by the U.S. Food and Drug Administration
- Casirivimab and imdevimab treatment has not been approved but has been authorized for emergency use by FDA under an EUA, to treat mild to moderate COVID19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.
- The emergency use of casirivimab and imdevimab is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization revoked sooner.